Rocket Pharmaceuticals Inc (RCKT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $256.82M
Last updated: Nov 17, 2026 at 11:06 AM ET
Rocket Pharmaceuticals Inc (RCKT) Stock Forecast
Analysts expect Rocket Pharmaceuticals (RCKT) to earn -$0.11 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.11M. Of 14 analysts, 7 rate the stock Buy or Strong Buy, 6 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.57, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 50% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 7.1% |
| Buy | 6 | 42.9% |
| Hold | 6 | 42.9% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 7.1% |
- Consensus
- Hold
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 913.5%.
- Fiscal year ending Dec 31, 2026
- -$0.11
- EPS consensus, revenue $1.11M
- Fiscal year ending Dec 31, 2027
- -$1.60
- EPS consensus, revenue $11.25M
- Next report
- Feb 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.11 | -$0.20 to $0.08 | 4 | $1.11M | N/A | 12 |
| Dec 31, 2027 | -$1.60 | -$1.84 to -$1.31 | 4 | $11.25M | N/A | 12 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.42 | -$0.45 to -$0.25 | 15 | $612000 | N/A | 13 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.90.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.11 | -$0.11 | -$0.11 | -$0.11 | -$0.90 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.60 | -$1.30 | -$1.30 | -$1.30 | -$1.22 | N/A |
Frequently Asked Questions About RCKT
What is the RCKT stock forecast?
Consensus analyst estimates put Rocket Pharmaceuticals's EPS at -$0.11 for the fiscal year ending Dec 31, 2026, on revenue of $1.11M. The consensus rating from 14 analysts is Hold.
How do analysts rate RCKT stock?
Of 14 analysts covering Rocket Pharmaceuticals, 1 rates it Strong Buy, 6 Buy, 6 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from RCKT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.11, with estimates from -$0.20 to $0.08 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.60, with estimates from -$1.84 to -$1.31 from 4 analysts.
What revenue do analysts expect from Rocket Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.11M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $11.25M.
How many analysts cover RCKT?
14 analysts rate Rocket Pharmaceuticals stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RCKT pages: Overview, Earnings, Forecast, Financials, Competitors